Loading...

vTv Therapeutics

DB:5VT
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
5VT
DB
$68M
Imp Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The last earnings update was 57 days ago. More info.


Add to Portfolio Compare Print
  • vTv Therapeutics has significant price volatility in the past 3 months.
5VT Share Price and Events
7 Day Returns
1.6%
DB:5VT
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-22.2%
DB:5VT
-7.4%
DE Biotechs
-5.6%
DE Market
5VT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
vTv Therapeutics (5VT) 1.6% -21.7% -58.1% -22.2% -78.7% -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 5VT underperformed the Biotechs industry which returned -7.4% over the past year.
  • 5VT underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
5VT
Industry
5yr Volatility vs Market
Related Companies

Value

 Is vTv Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether vTv Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as vTv Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for vTv Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €1.19.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for vTv Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are vTv Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:5VT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.69
NasdaqCM:VTVT Share Price ** NasdaqCM (2019-04-24) in USD $1.34
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of vTv Therapeutics.

DB:5VT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:VTVT Share Price ÷ EPS (both in USD)

= 1.34 ÷ -0.69

-1.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • vTv Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • vTv Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does vTv Therapeutics's expected growth come at a high price?
Raw Data
DB:5VT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for vTv Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on vTv Therapeutics's assets?
Raw Data
DB:5VT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-4.07
NasdaqCM:VTVT Share Price * NasdaqCM (2019-04-24) in USD $1.34
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:5VT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:VTVT Share Price ÷ Book Value per Share (both in USD)

= 1.34 ÷ -4.07

-0.33x

* Primary Listing of vTv Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • vTv Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of 5VT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through vTv Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess vTv Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. vTv Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is vTv Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is vTv Therapeutics expected to grow at an attractive rate?
  • Unable to compare vTv Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare vTv Therapeutics's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare vTv Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:5VT Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:5VT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:5VT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 5 -13 1
DB:5VT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 12 -27 -9
2018-09-30 8 -27 -11
2018-06-30 5 -33 -14
2018-03-31 2 -36 -15
2017-12-31 0 -45 -16
2017-09-30 0 -50 -16
2017-06-30 0 -51 -16
2017-03-31 0 -50 -17
2016-12-31 1 -48 -16
2016-09-30 1 -46 -15
2016-06-30 1 -43 -16
2016-03-31 1 -40 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if vTv Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if vTv Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:5VT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from vTv Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5VT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31 -0.53 -0.53 -0.53 1.00
DB:5VT Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.69
2018-09-30 -1.07
2018-06-30 -1.43
2018-03-31 -1.53
2017-12-31 -1.67
2017-09-30 -1.64
2017-06-30 -1.67
2017-03-31 -1.73
2016-12-31 -1.71
2016-09-30 -1.64
2016-06-30 -1.61
2016-03-31 -2.50

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if vTv Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess vTv Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
vTv Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has vTv Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare vTv Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • vTv Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare vTv Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare vTv Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
vTv Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from vTv Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5VT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 12.43 -8.65 9.22
2018-09-30 8.15 -11.13 10.09
2018-06-30 4.79 -13.99 10.50
2018-03-31 2.33 -14.88 10.76
2017-12-31 0.29 -16.14 11.33
2017-09-30 0.10 -15.88 10.65
2017-06-30 0.12 -16.23 10.48
2017-03-31 0.29 -16.72 10.15
2016-12-31 0.63 -16.35 9.91
2016-09-30 0.82 -15.47 10.02
2016-06-30 0.92 -15.58 10.04
2016-03-31 0.85 -21.54 9.66
2015-12-31 0.52 -27.50 9.08
2015-09-30 1.23 -32.04 8.85
2015-06-30 1.49 -33.81 8.02
2015-03-31 1.59 -30.80 8.59
2014-12-31 1.55 -36.10 11.72
2013-12-31 0.98 -48.20 8.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if vTv Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if vTv Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if vTv Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess vTv Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
vTv Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is vTv Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up vTv Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • vTv Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • vTv Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of vTv Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • vTv Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from vTv Therapeutics Company Filings, last reported 3 months ago.

DB:5VT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -20.37 15.71 2.81
2018-09-30 -24.07 18.21 4.89
2018-06-30 -32.18 19.09 3.47
2018-03-31 -28.39 19.86 8.79
2017-12-31 -19.61 19.59 11.76
2017-09-30 -5.66 19.31 20.49
2017-06-30 5.74 19.04 32.51
2017-03-31 18.19 18.76 45.15
2016-12-31 31.57 11.06 51.51
2016-09-30 43.91 0.00 51.06
2016-06-30 56.73 0.00 63.84
2016-03-31 70.65 0.00 75.50
2015-12-31 83.56 0.00 88.00
2015-09-30 94.07 0.00 97.01
2015-06-30 -80.95 55.48 2.40
2015-03-31 -70.53 44.99 0.78
2014-12-31 -60.72 36.17 1.38
2013-12-31 -74.36 83.17 1.16
  • vTv Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if vTv Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • vTv Therapeutics has less than a year of cash runway based on current free cash flow.
  • vTv Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -10.9% each year.
X
Financial health checks
We assess vTv Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. vTv Therapeutics has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is vTv Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from vTv Therapeutics dividends.
If you bought €2,000 of vTv Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate vTv Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate vTv Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:5VT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:5VT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as vTv Therapeutics has not reported any payouts.
  • Unable to verify if vTv Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of vTv Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as vTv Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess vTv Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can vTv Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. vTv Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of vTv Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Holcombe
COMPENSATION $459,400
AGE 61
TENURE AS CEO 4 years
CEO Bio

Mr. Stephen L. Holcombe, also known Steve, B.Sc. has been President & Chief Executive Officer of vTv Therapeutics Inc. since April 2015. Mr. Holcombe was the President and Chief Financial Officer of TransTech Pharma, LLC and High Point Pharmaceuticals, LLC from 2014 to March 2015, where he previously served as Senior Vice President and Chief Financial Officer from 2002 to 2014. Mr. Holcombe has over 35 years of experience in financial and Managerial roles focusing on the execution of private and public financings, developing corporate alliance and Partnership strategies and managing relationships with external constituents. Positions that Mr. Holcombe was Executive Vice President and Chief Financial Officer of Vanguard Cellular Systems, Inc., one of the largest independent wireless operators in the United States, Executive Vice President and Chief Financial Officer of BuildNet Inc., an e-commerce software solutions provider, and various positions with KPMG Peat Marwick Mitchell. He holds a bachelor’s degree in Accountancy from Wake Forest University.

CEO Compensation
  • Steve's compensation has been consistent with company performance over the past year.
  • Steve's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the vTv Therapeutics management team in years:

3.7
Average Tenure
60.5
Average Age
  • The tenure for the vTv Therapeutics management team is about average.
Management Team

Jeff Kindler

TITLE
Executive Chairman of the Board
COMPENSATION
$250K
AGE
62

Steve Holcombe

TITLE
President & CEO
COMPENSATION
$459K
AGE
61
TENURE
4 yrs

Rudy Howard

TITLE
Executive VP & CFO
COMPENSATION
$357K
AGE
60
TENURE
3.8 yrs

Carmen Valcarce

TITLE
Chief Scientific Officer & Executive VP

Robin Abrams

TITLE
Executive VP & General Counsel
AGE
54
TENURE
2.8 yrs

Aaron Burstein

TITLE
Senior Vice President of Clinical Development

Robert Andrews

TITLE
Senior Vice President of Chemistry

Imogene Dunn

TITLE
Senior Vice President of Biometrics and Regulatory

Samuel Rollins

TITLE
Senior Vice President of Intellectual Property
TENURE
3.6 yrs
Board of Directors Tenure

Average tenure and age of the vTv Therapeutics board of directors in years:

3.8
Average Tenure
58
Average Age
  • The tenure for the vTv Therapeutics board of directors is about average.
Board of Directors

Paul Savas

TITLE
Director
AGE
54
TENURE
4 yrs

Jeff Kindler

TITLE
Executive Chairman of the Board
COMPENSATION
$250K
AGE
62
TENURE
3.8 yrs

Steven Cohen

TITLE
Director
AGE
55
TENURE
3.8 yrs

Noel Spiegel

TITLE
Independent Director
COMPENSATION
$71K
AGE
70
TENURE
3.8 yrs

Craig Parker

TITLE
Independent Director
COMPENSATION
$67K
AGE
56
TENURE
3.8 yrs

Howard Weiner

TITLE
Independent Director
COMPENSATION
$72K
AGE
73
TENURE
1.8 yrs

John Fry

TITLE
Independent Director
COMPENSATION
$64K
AGE
58
TENURE
3.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
28. Feb 19 Buy MacAndrews & Forbes Holdings, Inc. Company 28. Feb 19 28. Feb 19 815,217 €1.62 €1,317,149
30. Nov 18 Buy MacAndrews & Forbes Group Inc. Company 29. Nov 18 29. Nov 18 1,879,700 €1.17 €2,196,999
28. Dec 18 Buy MacAndrews & Forbes Group Inc. Company 27. Dec 18 27. Dec 18 815,217 €1.61 €1,314,749
30. Nov 18 Buy MacAndrews & Forbes Holdings, Inc. Company 29. Nov 18 29. Nov 18 1,879,700 €1.17 €2,197,001
10. Sep 18 Buy Ronald Perelman Individual 06. Sep 18 06. Sep 18 1,879,699 €1.14 €2,152,000
06. Sep 18 Buy Paul Savas Individual 06. Sep 18 06. Sep 18 5,000 €0.86 €4,304
14. Aug 18 Buy Ronald Perelman Individual 10. Aug 18 10. Aug 18 570,777 €3.84 €2,189,753
10. Jul 18 Buy Ronald Perelman Individual 06. Jul 18 06. Jul 18 570,776 €3.73 €2,126,499
X
Management checks
We assess vTv Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. vTv Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer’s disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase IIb clinical trials to treat type 2 diabetes, as well as is in Phase II clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing a portfolio of investigational drug candidates, such as HPP737 and HPP971 to treat inflammatory disorders. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Details
Name: vTv Therapeutics Inc.
5VT
Exchange: DB
Founded: 2015
$60,733,650
$32,633,292
50,350,184
Website: http://www.vtvtherapeutics.com
Address: vTv Therapeutics Inc.
4170 Mendenhall Oaks Parkway,
High Point,
North Carolina, 27265,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM VTVT Class A Common Stock Nasdaq Capital Market US USD 30. Jul 2015
DB 5VT Class A Common Stock Deutsche Boerse AG DE EUR 30. Jul 2015
Number of employees
Current staff
Staff numbers
52
vTv Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:55
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/03/18
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.